In 2010, electroCore achieved a technical breakthrough, developing the ability to administer vagus nerve stimulation non-invasively (nVNS) by delivering a proprietary signal through the skin to either the right or left branches of the vagus nerve in the neck.

In Australia, gammaCore is indicated for the treatment and/or prevention of primary headache (migraine, cluster headache, and hemicrania continua) and medication overuse headache in adults.

gammaCore is available in Australia on authorisation by a registered healthcare professional.